1 |
Aitken SJ, Thomas JS, Langdon SP, et al (2010). Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol, 21, 1254-61.
DOI
|
2 |
Arapantoni-Dadioti P, Valavanis C, Gavressea T, et al. (2012). Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases. J BUON, 17, 277-83.
|
3 |
Ba JL, Liu CG, Jin F (2014). Alterations in hormonal receptor expression and HER2 status between primary breast tumors and paired nodal metastases: discordance rates and prognosis. Asian Pac J Cancer Prev, 15, 9233-9.
DOI
|
4 |
Bagaria SP, Ray PS, Sim MS, et al.(2014). Personalizing breast cancer staging by the inclusion of ER, PR, and HER2. JAMA Surg, 149, 125-9.
DOI
|
5 |
Brouckert O, Paridaens R, Floris G, et al. (2012). A critical review why assessment of steroid hormone receptors in breast cancer should be quantitative. Ann Oncol. 10, 1-7.
|
6 |
Chen W, Yang H, Tang WR, et al. (2014). Updated Meta-analysis on HER2 Polymorphisms and Risk of Breast Cancer: Evidence from 32 Studies. Asian Pac J Cancer Prev, 15, 9643-7.
DOI
|
7 |
Falck AK, Ferno M, Bendahl PO, et al. (2010). Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer?. World J Surg, 34, 1434-41.
DOI
|
8 |
Hoefnagel LD, van de Vijver MJ, van Slooten HJ, et al. (2010). Receptor conversion in distant breast cancer metastases. Breast Cancer Res, 12, 75-7.
DOI
|
9 |
Huang TH, Wu Fand Loeb GB, et al. (2009). Upregulation of miR-21 by HER2/neu signaling promotes cell invasion. J Biol Chem, 284, 18515-24.
DOI
|
10 |
Ibrahim T, Farolfi A, Scarpi E, et al. (2013). Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact. Oncology, 84, 150-7.
DOI
|
11 |
Jabbour MN, Massad CY, Boulos FI (2012). Variability in hormone and growth factor receptor expression in primary versus recurrent, metastatic, and post-neoadjuvant breast carcinoma. Breast Cancer Res Treat, 135, 29-37.
DOI
|
12 |
Kinsella MD, Nassar A, Siddiqui MT, et al. (2012). Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience. Int J Clin Exp Pathol, 5, 530-6.
|
13 |
Salim DK, Mutlu H, Eryilmaz MK, et al. (2014). Molecular Types and Neoadjuvant Chemotherapy in Patients with Breast Cancer- While Molecular Shifting is More Common in Luminal a Tumors, The Pathologic Complete Response is Most Frequently Observed in Her-2 Like Tumors. Asian Pac J Cancer Prev, 15, 9379-83.
DOI
|
14 |
Lindstrom LS, Karlsson E, Wilking UM, et al. (2012). Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol, 20, 2601-8.
|
15 |
Maynadier M, Nirde P, Ramirez JM, et al. (2008). Role of estrogens and their receptors in adhesion and invasiveness of breast cancer cells. Adv Exp Med Biol, 617, 485-491.
DOI
|
16 |
Patani N, Martin LA, Dowsett M. (2013). Biomarkers for the clinical management of breast cancer: international perspective. Int J Cancer, 133, 1-13.
DOI
|
17 |
Thompson A. M , Jordan L B, Quinlan P, et al. (2010). Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res, 12, 92-5.
DOI
|
18 |
Rokutanda N, Horiguchi D, Takata D,et al.(2012). Comparison of hormone receptor and HER2 expression in primary breast cancers and sentinel lymph node metastasis. Cancer Res, 72, 2-5-7.
DOI
|
19 |
www.cap.org/aps/docs/committees/.../summary of recommendations.pdf.
|